Home » Newsletters » BioWorld Science

BioWorld Science

March 27, 2017

View Archived Issues

Avrobio adds gene therapy for Gaucher disease to pipeline

EMA committee recommends approval of Axumin for use in prostate cancer

C4 Therapeutics and Calico partner to develop therapeutics based on targeted protein degradation

PureTech Health signs licensing and equity agreement with Novartis for mTORC1 programs

EMA committee recommends approval of Keytruda for classical Hodgkin's lymphoma

Japanese orphan drug designation for olaparib in BRCA-mutated ovarian cancer

ImmunoGen decides not to exercise late-stage co-development option for BT-062

EMA accepts Shionogi's MAA submission for naldemedine

ANP-C shown to be a novel target for pulmonary arterial hypertension

TB Alliance sublicenses sutezolid from Medicines Patent Pool

Boehringer Ingelheim Pharma GmbH discloses free fatty acid receptor 1 agonists

EMA committee recommends approval of Trumenba

Erytech reports topline results from phase IIb study of eryaspase in metastatic pancreatic cancer

First potential fluid-based biomarker of ALS disease progression identified

Sublingual bacterial vaccine Uromune shows safety and efficacy for recurrent UTIs

Opdivo approved in Japan for head and neck cancer, recommended for approval in E.U.

AnGes files IND to begin clinical trial of NF-kappaB decoy for the treatment of disc pain

Japanese approval expands Sovaldi indication

Estetrol demonstrates potential utility in the treatment of prostate cancer

Tagrisso approved in China for NSCLC

Neuren reports phase II topline results for trofinetide in Rett syndrome

Bile acid receptor found to be a target for treating neuroinflammation

EMA validates regulatory filing of tildrakizumab in Europe

Refixia recommended for approval in E.U.

VIB and DNAlytics partner on colorectal cancer screening test

French approval for Eprex within E.U. mutual recognition procedure

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...